


Author's Accepted Manuscript

Efficacy, Safety, and Pharmacokinetics of Natalizumab in Japanese Multiple Sclerosis Patients: A Double-blind, Randomized Controlled Trial and Open-label Pharmacokinetic Study

Takahiko Saida, Jun-ichi Kira, Shuji Kishida, Takashi Yamamura, Yukiko Sudo, Kazutaka Ogiwara, JT Tibung, Nisha Lucas, Meena Subramanyam



PII: S2211-0348(16)30197-3
DOI: <http://dx.doi.org/10.1016/j.msard.2016.11.002>
Reference: MSARD488

To appear in: *Multiple Sclerosis and Related Disorders*

Received date: 23 February 2016
Revised date: 21 September 2016
Accepted date: 4 November 2016

Cite this article as: Takahiko Saida, Jun-ichi Kira, Shuji Kishida, Takashi Yamamura, Yukiko Sudo, Kazutaka Ogiwara, JT Tibung, Nisha Lucas and Meena Subramanyam, Efficacy, Safety, and Pharmacokinetics of Natalizumab in Japanese Multiple Sclerosis Patients: A Double-blind, Randomized Controlled Trial and Open-label Pharmacokinetic Study, *Multiple Sclerosis and Related Disorders*, <http://dx.doi.org/10.1016/j.msard.2016.11.002>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Efficacy, Safety, and Pharmacokinetics of Natalizumab in Japanese
Multiple Sclerosis Patients: A Double-blind, Randomized Controlled Trial
and Open-label Pharmacokinetic Study**

Takahiko Saida^{a*}, Jun-ichi Kira^b, Shuji Kishida^c, Takashi Yamamura^d, Yukiko Sudo^e, Kazutaka Ogiwara^e, JT Tibung^e, Nisha Lucas^f, Meena Subramanyam^f,
on behalf of Natalizumab Trial Principal Investigators

^aKansai Multiple Sclerosis Center and Kyoto Min-iren Central Hospital, Kyoto, Japan;

^bDepartment of Neurology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan;

^cHakusuikai Hatsuishi Hospital, Chiba, Japan;

^dNational Center of Neurology and Psychiatry (NCNP), Tokyo, Japan;

^eBiogen Japan, Tokyo, Japan; ^fBiogen, Cambridge, MA, USA

***Correspondence:** Takahiko Saida, MD, PhD, Kansai Multiple Sclerosis Center, Nishinokyo-Kasuga-cho 16-44-409, Nakakyo-ku, Kyoto, 604-8453, Japan. Tel.: +81-75-468-8642; fax: +81-75-802-2380. Email: saida_takahiko@maia.eonet.ne.jp

Download English Version:

<https://daneshyari.com/en/article/5590817>

Download Persian Version:

<https://daneshyari.com/article/5590817>

[Daneshyari.com](https://daneshyari.com)